About
Healthspan Action Coalition (HSAC) is a nonprofit advocacy and policy research organization working to extend global human healthspan by uniting stakeholders across science, industry, regulatory bodies, and patient advocacy groups. The organization focuses on advancing new medical strategies that intervene in the aging process and improve treatment of age-related diseases including dementia, heart disease, cancer, and frailty. Rather than offering direct consumer products or services, HSAC operates as a cross-sector societal movement that brings together 120+ organizations to accelerate the discovery, development, and delivery of healthspan-extending treatments.
HSAC's core work centers on three strategic priorities: increasing government funding for longevity research and clinical trials, establishing accelerated regulatory pathways for healthspan treatments, and advancing payment policies that support patient access to regenerative medicine and advanced therapies. The organization also advocates for reducing unnecessary preclinical animal testing in favor of advanced technologies like precision medicine, organ-on-chip systems, AI, organoids, and tissue engineering. This approach recognizes that aging itself is a disease-related condition and that the aging process is the primary risk factor for virtually all noncommunicable diseases.
Beyond policy work, HSAC drives workforce development initiatives, publishes The Healthspan Compass newsletter, and recently proposed landmark legislation called the THRIVE Act (Therapeutic Healthspan Research, Innovation, and Validation Enhancement Act) to incentivize development and facilitate regulatory approval of innovative healthspan-extending products including drugs, nutritionals, devices, and diagnostics. The organization's mission centers on making healthspan a fundamental human right and ensuring that discoveries in healthy longevity reach all populations regardless of ethnicity or economic status.
Longevity Contribution
- Operates as a unified coalition of 120+ organizations across science, industry, regulatory bodies, and patient advocacy rather than a single company
- Proposes and advocates for specific legislation (THRIVE Act) to accelerate regulatory approval and funding for healthspan treatments
- Addresses health equity and structural barriers by explicitly prioritizing delivery of healthspan interventions to all populations and communities
- Focuses on emerging technology adoption including cellular reprogramming, gene editing, AI, tissue engineering, and robotics while maintaining ethical responsibility standards
